SEATTLE, June 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced that it has filed a universal shelf registration statement with the U.S. Securities and Exchange Commission, registering $150 million worth of securities to be offered and sold by CTI from time to time. The number and price of the securities will be determined at the time the securities are sold.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sales would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact: Cell Therapeutics, Inc. Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: media@ctiseattle.comhttp://www.cticseattle.com/media.htm Investors Contact: Cell Therapeutics, Inc. Leah Grant T: 206.282.7100 F: 206.272.4434 E: invest@ctiseattle.comhttp://www.cticseattle.com/investors.htm
Cell Therapeutics, Inc.
CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, fax +1-206-272-4434, media@ctiseattle.com,or investors, Leah Grant, +1-206-282-7100, fax +1-206-272-4434,invest@ctiseattle.com, all of Cell Therapeutics, Inc.
Web site: http://www.cticseattle.com/
